JP2013533310A - 苦味物質を使用して閉塞性肺疾患を処置する方法 - Google Patents

苦味物質を使用して閉塞性肺疾患を処置する方法 Download PDF

Info

Publication number
JP2013533310A
JP2013533310A JP2013524091A JP2013524091A JP2013533310A JP 2013533310 A JP2013533310 A JP 2013533310A JP 2013524091 A JP2013524091 A JP 2013524091A JP 2013524091 A JP2013524091 A JP 2013524091A JP 2013533310 A JP2013533310 A JP 2013533310A
Authority
JP
Japan
Prior art keywords
bitter
subject
smooth muscle
bitter taste
airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2013524091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533310A5 (enExample
Inventor
ビー・リゲット スティーヴン
シー．エイチ・ワン ウェイン
エー・デシュパンド ディーパック
Original Assignee
ユニバーシティー オブ メリーランド，ボルティモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ メリーランド，ボルティモア filed Critical ユニバーシティー オブ メリーランド，ボルティモア
Publication of JP2013533310A publication Critical patent/JP2013533310A/ja
Publication of JP2013533310A5 publication Critical patent/JP2013533310A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013524091A 2010-08-09 2011-07-27 苦味物質を使用して閉塞性肺疾患を処置する方法 Abandoned JP2013533310A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37194610P 2010-08-09 2010-08-09
US61/371,946 2010-08-09
US40588310P 2010-10-22 2010-10-22
US61/405,883 2010-10-22
PCT/US2011/045537 WO2012021291A2 (en) 2010-08-09 2011-07-27 Methods of treating obstructive lung diseases using bitter tastants

Publications (2)

Publication Number Publication Date
JP2013533310A true JP2013533310A (ja) 2013-08-22
JP2013533310A5 JP2013533310A5 (enExample) 2014-09-11

Family

ID=45568120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524091A Abandoned JP2013533310A (ja) 2010-08-09 2011-07-27 苦味物質を使用して閉塞性肺疾患を処置する方法

Country Status (4)

Country Link
US (1) US9579315B2 (enExample)
EP (1) EP2603213A4 (enExample)
JP (1) JP2013533310A (enExample)
WO (1) WO2012021291A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506639A (ja) * 2014-02-14 2017-03-09 カインド・コンシューマー・リミテッドＫｉｎｄ Ｃｏｎｓｕｍｅｒ Ｌｉｍｉｔｅｄ カンナビノイド組成物および使用
KR102140493B1 (ko) * 2019-05-30 2020-08-03 충북대학교 산학협력단 데나토늄을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742350B1 (en) * 2011-08-08 2019-10-30 The Coca-Cola Company Cell lines comprising endogenous taste receptors and their uses
WO2013112865A1 (en) * 2012-01-27 2013-08-01 The Trustees Of The University Of Pennsylvania Diagnosis and treatment for respiratory tract diseases
WO2014022139A1 (en) * 2012-07-31 2014-02-06 University Of Massachusetts Medical School Methods for identifying agents for treating smooth muscle disorders and compositions thereof
PL2865421T3 (pl) * 2013-10-28 2018-10-31 Albert-Ludwigs-Universität Freiburg Agoniści receptora gorzkiego smaku do stosowania miejscowego
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
WO2020010166A1 (en) * 2018-07-02 2020-01-09 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for asthma
US12268660B2 (en) 2018-07-11 2025-04-08 Aardvark Therapeutics Inc. Oral pharmaceutical formulations of bitter compounds for pulmonary hypertension
WO2021211923A1 (en) * 2020-04-16 2021-10-21 Pulmoquine Therapeutics, Inc. Compositions and methods for treating disease
US12257248B2 (en) * 2020-09-01 2025-03-25 University Of South Florida Bronchodilators for treating obstructive lung disease
CN113694053A (zh) * 2021-09-29 2021-11-26 常州大学 氟芬那酸作为有效成分在制备气道平滑肌舒张剂中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0851759A4 (en) * 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
CA2372443C (en) * 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
US7364867B2 (en) * 2000-04-17 2008-04-29 The Mount Sinai School Of Medicine Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells
US7368285B2 (en) 2001-03-07 2008-05-06 Senomyx, Inc. Heteromeric umami T1R1/T1R3 taste receptors and isolated cells that express same
US7794959B2 (en) * 2001-04-05 2010-09-14 Senomyx, Inc. Identification of bitter receptors for hydrolyzed soy protein
US7883856B2 (en) * 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
EP1851548A4 (en) * 2005-02-08 2010-04-28 Senomyx Inc HUMAN T2R RECEPTORS FOR ACETAMINOPHES, RANITIDINE, STRYCHNIN AND DENATONIUM, AND ASSOCIATED ASSAYS FOR IDENTIFYING MODULATORS BITTER TASTE
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
AU2006299383A1 (en) * 2005-10-04 2007-04-12 Nitromed, Inc. Methods for treating respiratory disorders
WO2008141438A1 (en) * 2007-05-17 2008-11-27 Sunnybrook Health Sciences Centre Gabaergic modulators for treating airway conditions
WO2010011813A1 (en) * 2008-07-23 2010-01-28 Alkermes, Inc. Complex of trospium and pharmaceutical compositions thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017506639A (ja) * 2014-02-14 2017-03-09 カインド・コンシューマー・リミテッドＫｉｎｄ Ｃｏｎｓｕｍｅｒ Ｌｉｍｉｔｅｄ カンナビノイド組成物および使用
KR102140493B1 (ko) * 2019-05-30 2020-08-03 충북대학교 산학협력단 데나토늄을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
US20130131108A1 (en) 2013-05-23
EP2603213A4 (en) 2014-02-19
EP2603213A2 (en) 2013-06-19
US9579315B2 (en) 2017-02-28
WO2012021291A3 (en) 2012-05-18
WO2012021291A2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US9579315B2 (en) Methods of treating obstructive lung diseases using bitter tastants
JP2020143087A (ja) 障害を治療するための５ｈｔ作動薬
Pozzo-Miller et al. Rett syndrome: reaching for clinical trials
CN108420819A (zh) 用于治疗神经障碍的新组合物
US20110081428A1 (en) Use of thioflavin-like compounds to increase life span and/or health span
US20230098944A1 (en) Method of decreasing amyloid beta monomer levels in patients with cognitive decline
CN103221043B (zh) 用于治疗神经元连接发育障碍的erk抑制剂
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
CA2669123A1 (en) Acat inhibitors and their use in the prevention or treatment of fibrosis
JP2017119722A (ja) タウ凝集阻害剤
EP1817039A2 (en) Treatment and prevention of epilepsy
JP6352926B2 (ja) 炎症性肺疾患を治療するための治療剤
C Brett et al. Current therapeutic advances in patients and experimental models of Huntington's disease
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
US20080269325A1 (en) Methods to Relieve Pain
EP2830620A1 (en) 4 aminopyridine as a therapeutic agent for spinal muscular atrophy
US20220331301A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal resessive polycystic kidney disease
US20230372311A1 (en) Compositions and methods of treating age-related retinal dysfunction
EP4656194A1 (en) Composition for preventing or treating post-traumatic stress disorder, comprising phosphodiesterase type 5 inhibitor as active ingredient
JP2025531823A (ja) Ｃｌｅｃ１６ａの機能不全または欠損に関連する症状を改善するための組成物および方法
JP2024521282A (ja) 抗うつ・抗不安の置換桂皮アミド化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140722

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20140829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140829